<description>In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB.  Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.</description>

In this episode, we're joined by Dr. Richard Menz…

In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB.  Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.

Episode 4 - Dr. Richard Menzies and Dr. Jonathan Campbell - 4 months of Rifampin for latent TB

<description>In this episode, we're joined by MD/PhD student Matthew Dankner to discuss his paper "Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma" published in the June 2018 issue of Clinical Cancer Research.</description>

In this episode, we're joined by MD/PhD student M…

In this episode, we're joined by MD/PhD student Matthew Dankner to discuss his paper "Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma" published in the June 2018 issue of Clinical Cancer Research.

Episode 3 - Matthew Dankner - Dual MAPK inhibition in a subset of BRAF mutant melanomas

<description>On this episode we're very grateful to have interviewed PhD candidate Devin Abrahami, the first author of the paper "Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study" published in the March 2018 issue of the British Medical Journal.  This paper from the group of Dr. Laurent Azoulay really made a lot of waves in the medical community, achieving an Altmetric score of 320 and still climbing and is a must-read.</description>

On this episode we're very grateful to have inter…

On this episode we're very grateful to have interviewed PhD candidate Devin Abrahami, the first author of the paper "Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study" published in the March 2018 issue of the British Medical Journal.  This paper from the group of Dr. Laurent Azoulay really made a lot of waves in the medical community, achieving an Altmetric score of 320 and still climbing and is a must-read.

Episode 2 - Devin Abrahami - DPP-4 inhibitors and incidence of IBD among patients with DMII

<description>Paul Savage is an MD-PhD student in the lab of Dr. Morag Park at the Goodman Cancer Research Centre in Montreal, Canada.  In this episode, we discuss his latest article published in the October 2017 edition of Cell Reports.  Using a patient-derived xenograft model to screen triple negative breast cancer (TNBC) tumours for susceptibility to targeted therapies, he and his colleagues identified an exceptional responder to treatment with the epidermal growth factor receptor (EGFR) inhibitor gefitinib.  Single-cell RNA sequencing and functional assays were used to characterize a new tumour-initiating program within this exceptional responder, which may represent a new target in the treatment of a subset of TNBC patients.</description>

Paul Savage is an MD-PhD student in the lab of Dr…

Paul Savage is an MD-PhD student in the lab of Dr. Morag Park at the Goodman Cancer Research Centre in Montreal, Canada.  In this episode, we discuss his latest article published in the October 2017 edition of Cell Reports.  Using a patient-derived xenograft model to screen triple negative breast cancer (TNBC) tumours for susceptibility to targeted therapies, he and his colleagues identified an exceptional responder to treatment with the epidermal growth factor receptor (EGFR) inhibitor gefitinib.  Single-cell RNA sequencing and functional assays were used to characterize a new tumour-initiating program within this exceptional responder, which may represent a new target in the treatment of a subset of TNBC patients.

Episode 1 - Paul Savage - A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

Hey there, and welcome to The MUMPS: The McGill University Medical Podcast Series!  This is a podcast geared towards aspiring, training or practicing health care professionals who are looking to keep up to date with the latest medical research going on at McGill and its affiliated institutions.  Tune in monthly as your hosts Russ and Eric chat with basic science and clinical researchers behind some of McGill University's most current, influential and thought-provoking medical research.

Mcgill University Medical Podcast Series

Details

Recent Episodes